Olutasidenib + Hypomethylating Agent combination
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-20 — A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm: Phase 2 trial launched evaluating olutasidenib + HMA combination for safety and efficacy in IDH1-mutated higher-risk MDS, CMML, or advanced MPN — first prospective test of this targeted combination in this molecular subgroup (trial-early). (novelty: 3)
Open questions
Related
Contributing findings
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
20-may-2026
novelty 3
per-area 3
introduces